Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
COMBIVENT vs A-METHAPRED
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combivent is a fixed-dose combination of ipratropium bromide, an anticholinergic agent that inhibits muscarinic receptors in bronchial smooth muscle leading to bronchodilation, and albuterol sulfate, a beta-2 adrenergic agonist that stimulates adenyl cyclase, increasing cyclic AMP, resulting in bronchodilation.
Methylprednisolone is a synthetic glucocorticoid that binds to the glucocorticoid receptor, leading to modulation of gene expression and suppression of inflammatory mediators such as cytokines, prostaglandins, and leukotrienes. It also induces lipocortin synthesis, inhibits phospholipase A2, and reduces immune cell activity.
Treatment of chronic obstructive pulmonary disease (COPD) exacerbations,Acute asthma exacerbations (off-label)
Allergic reactions (severe or disabling),Dermatologic diseases (e.g., pemphigus, exfoliative dermatitis),Endocrine disorders (e.g., congenital adrenal hyperplasia, nonsuppurative thyroiditis),Gastrointestinal diseases (e.g., ulcerative colitis, Crohn's disease),Hematologic disorders (e.g., autoimmune hemolytic anemia, thrombocytopenia),Neoplastic diseases (e.g., leukemia, lymphoma),Nervous system disorders (e.g., multiple sclerosis exacerbations),Ophthalmic diseases (e.g., allergic conjunctivitis, optic neuritis),Renal diseases (e.g., nephrotic syndrome, lupus nephritis),Respiratory diseases (e.g., asthma exacerbations, sarcoidosis),Rheumatic disorders (e.g., rheumatoid arthritis, acute gouty arthritis),Organ transplantation (as part of immunosuppressive regimen)
2 inhalations (ipratropium 18 mcg and albuterol 103 mcg per actuation) via oral inhalation 4 times daily; maximum 12 inhalations in 24 hours.
Initial 4-48 mg/day oral in divided doses, tapered. For pulse therapy: 1 g IV daily for 3 days.
Ipratropium: terminal elimination half-life of approximately 2 hours (range 1.5-4 hours) after inhalation. Albuterol: terminal elimination half-life of approximately 3.8-6 hours after inhalation; systemic half-life is clinically relevant for dosing frequency in asthma/COPD.
2-3 hours (terminal); clinical effect persists longer due to intracellular receptor binding.
Ipramatropium: partially metabolized by hydrolysis to inactive metabolites; Albuterol: primarily metabolized by sulfate conjugation via SULT1A3 and to a lesser extent by CYP450 enzymes (CYP3A4, CYP2D6) to 4'-O-sulfate.
Primarily hepatic via CYP3A4 enzyme system, with minor contributions from other pathways.
Ipratropium is primarily excreted renally as unchanged drug (approximately 50%) and metabolites (approximately 30%); fecal excretion accounts for about 10%. Albuterol undergoes hepatic metabolism to an inactive sulfate conjugate, with approximately 70-80% of a dose excreted renally as unchanged drug and metabolite; fecal excretion is minimal (<10%).
Renal (mainly as inactive metabolites); <5% unchanged. Biliary/fecal excretion is minimal.
Ipratropium: approximately 0-9% bound to plasma proteins (predominantly albumin). Albuterol: approximately 10% bound to plasma proteins.
74-90% bound primarily to corticosteroid-binding globulin (CBG) and albumin.
Ipratropium: Vd approximately 2-4 L/kg (467 L for a 70 kg adult), indicating extensive tissue distribution. Albuterol: Vd approximately 1.5-2 L/kg (105-140 L for a 70 kg adult), consistent with moderate tissue distribution.
1.0-1.5 L/kg; indicates extensive tissue distribution.
Inhalation: Ipratropium absolute bioavailability of approximately 7-25% (due to pulmonary deposition and swallowed fraction). Albuterol inhaled bioavailability of approximately 10-20%. Oral bioavailability (swallowed) is low: ipratropium about 2-3%, albuterol about 30-50% but first-pass metabolism reduces systemic exposure.
Oral: ~80%; IM: ~100%.
No dose adjustment required for mild-to-moderate renal impairment (Cr Cl >30 m L/min). Caution in severe impairment (Cr Cl <30 m L/min) or dialysis; use reduced frequency or alternative therapy due to potential for systemic accumulation.
No specific dose adjustment required; use caution in severe renal impairment.
No specific Child-Pugh based guidelines; caution in severe hepatic impairment (Child-Pugh class C) due to reduced clearance of albuterol, consider dose reduction or extended interval.
No specific guidelines; caution in severe hepatic impairment.
Not recommended for children <6 years. For ≥6 years: 2 inhalations 4 times daily as needed, up to 12 inhalations/day.
0.5-1.7 mg/kg/day or 5-25 mg/m²/day in divided doses.
No specific dose adjustment; monitor for anticholinergic effects (e.g., dry mouth, urinary retention) and beta-adrenergic effects (e.g., tachycardia, tremor). Ensure proper inhaler technique; consider spacer use.
Lower initial doses recommended due to increased risk of osteoporosis, fluid retention, and immunosuppression.
None
Corticosteroids, including methylprednisolone, may cause immunosuppression and increase susceptibility to infections. Live or live attenuated vaccines are contraindicated in patients receiving immunosuppressive doses. Administration of live vaccines may cause disseminated infection.
Paradoxical bronchospasm,Immediate hypersensitivity reactions,Deterioration in renal function (ipratropium eliminated renally),Cardiovascular effects: tachycardia, arrhythmias, hypertension (albuterol),Hypokalemia (albuterol),Increased intraocular pressure with nebulized ipratropium in glaucoma patients,Urinary retention in patients with prostatic hyperplasia or bladder neck obstruction
Increased risk of infections; monitor for signs of infection and avoid exposure to active infections.,Adrenal suppression may occur, especially with prolonged therapy; taper dosing gradually.,May cause fluid and electrolyte disturbances (e.g., sodium retention, potassium loss, hypertension).,Gastrointestinal perforation risk, especially in patients with inflammatory bowel disease or recent GI surgery.,Osteoporosis with long-term use.,Behavioral and mood disturbances (e.g., euphoria, depression, psychosis).,Cushing's syndrome with chronic use.,Exacerbation of diabetes mellitus, glaucoma, and cataracts.,High-dose therapy may cause acute myopathy, particularly in patients on neuromuscular blocking agents.
Hypersensitivity to ipratropium, albuterol, or any component of the formulation,Hypersensitivity to atropine or its derivatives
Systemic fungal infections,Hypersensitivity to methylprednisolone or any component of the formulation,Administration of live or live attenuated vaccines in immunosuppressive doses,Idiopathic thrombocytopenic purpura (IM route only)
No specific food interactions are clinically significant. Avoid excessive caffeine intake (coffee, tea, cola, chocolate) as it may increase the risk of stimulant side effects (tremor, palpitations). Maintain adequate hydration to help manage possible dry mouth from ipratropium.
Avoid grapefruit and grapefruit juice as they may increase methylprednisolone levels. Limit sodium intake to reduce fluid retention. Avoid alcohol due to increased risk of gastrointestinal bleeding. Maintain adequate calcium and vitamin D intake to prevent bone loss.
Pregnancy Category C. No adequate well-controlled studies in pregnant women. In animal studies, albuterol sulfate showed teratogenicity (cleft palate) at high doses; ipratropium bromide showed no teratogenic effects. Risk cannot be ruled out; use only if potential benefit justifies potential risk to fetus. First trimester: potential risk based on animal data. Second/third trimesters: albuterol may inhibit uterine contractions and cause maternal tachycardia, which may affect fetal heart rate; avoid near term due to possible neonatal hypoglycemia and hypokalemia.
First trimester: Corticosteroids are associated with a small increased risk of oral clefts (odds ratio ~1.5). Second and third trimesters: Chronic use may lead to fetal adrenal suppression, intrauterine growth restriction, and preterm birth. Risk is dose- and duration-dependent.
Unknown if albuterol or ipratropium are excreted in human milk. M/P ratio not established. Caution advised; consider developmental and health benefits of breastfeeding along with mother's clinical need and potential adverse effects on nursing infant.
Prednisolone (active metabolite) is excreted into breast milk, with an M/P ratio approximately 5:1 to 20:1. The relative infant dose is estimated at <10% of maternal weight-adjusted dose. Monitor infant for adrenal suppression and growth. Nursing should be timed 3-4 hours after maternal dose.
No specific dosing adjustment recommended for Combivent during pregnancy. Pharmacokinetic changes in pregnancy (increased volume of distribution, renal clearance) may affect albuterol; monitor clinical response and adjust dosing frequency if needed. Ipratropium has minimal systemic absorption; no adjustment anticipated.
Dose adjustment may be necessary due to increased clearance of prednisolone in pregnancy. Dose should be individualized, often with increased doses during pregnancy and reduced postpartum. No standard fixed adjustment; monitor clinical response.
Combivent is a fixed-dose combination of ipratropium bromide (anticholinergic) and albuterol sulfate (beta-2 agonist) for COPD exacerbations. It should be used with caution in patients with narrow-angle glaucoma, bladder neck obstruction, or prostatic hypertrophy. Shake well before use. Rinse mouth after inhalation to prevent oral candidiasis and dysphonia. Monitor for paradoxical bronchospasm, hypokalemia, and cardiovascular effects (tachycardia, hypertension). Not indicated for acute episodes of asthma or as rescue monotherapy; consider separate short-acting beta-agonist for acute symptoms.
A-Methapred is a brand of methylprednisolone sodium succinate. For acute spinal cord injury, administer within 8 hours with a bolus of 30 mg/kg over 15 minutes, followed by a 45-minute pause, then 5.4 mg/kg/hour for 23 hours. Monitor for hyperglycemia, especially in diabetic patients; consider insulin sliding scale. Taper dose if used for >5 days to avoid adrenal insufficiency. Avoid abrupt discontinuation.
Use exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Shake the inhaler well before each use (at least 10-15 seconds).,Prime the inhaler by spraying 4 test sprays into the air (away from face) before first use or if not used for more than 3 days.,Rinse your mouth with water after each use to reduce the risk of thrush (oral fungal infection) and hoarseness.,Seek immediate medical attention if you experience sudden worsening of breathing, chest pain, or signs of allergic reaction (rash, hives, swelling).,Inform your doctor if you have glaucoma, difficulty urinating, enlarged prostate, heart problems, or seizures.,Do not use with other inhaled medicines unless instructed by your doctor.,Keep inhaler clean; wipe mouthpiece with a dry cloth weekly.
Do not stop taking this medication suddenly without consulting your doctor; dosage must be tapered gradually.,Report any signs of infection (fever, sore throat, cough) or unusual bleeding/bruising immediately.,Avoid live vaccines while on this medication.,Take with food or milk to reduce stomach upset.,Carry a medical alert card stating you are taking corticosteroids.,Do not miss doses; take exactly as prescribed.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about COMBIVENT vs A-METHAPRED, answered by our medical review team.
COMBIVENT is a Bronchodilator Combination (Anticholinergic + Beta-2 Agonist) that works by Combivent is a fixed-dose combination of ipratropium bromide, an anticholinergic agent that inhibits muscarinic receptors in bronchial smooth muscle leading to bronchodilation, and albuterol sulfate, a beta-2 adrenergic agonist that stimulates adenyl cyclase, increasing cyclic AMP, resulting in bronchodilation.. A-METHAPRED is a Corticosteroid that works by Methylprednisolone is a synthetic glucocorticoid that binds to the glucocorticoid receptor, leading to modulation of gene expression and suppression of inflammatory mediators such as cytokines, prostaglandins, and leukotrienes. It also induces lipocortin synthesis, inhibits phospholipase A2, and reduces immune cell activity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between COMBIVENT and A-METHAPRED depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of COMBIVENT is: 2 inhalations (ipratropium 18 mcg and albuterol 103 mcg per actuation) via oral inhalation 4 times daily; maximum 12 inhalations in 24 hours.. The standard adult dose of A-METHAPRED is: Initial 4-48 mg/day oral in divided doses, tapered. For pulse therapy: 1 g IV daily for 3 days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between COMBIVENT and A-METHAPRED in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. COMBIVENT is classified as Category C. Pregnancy Category C. No adequate well-controlled studies in pregnant women. In animal studies, albuterol sulfate showed teratogenicity (cleft palate) at high doses; ipratropium br. A-METHAPRED is classified as Category C. First trimester: Corticosteroids are associated with a small increased risk of oral clefts (odds ratio ~1.5). Second and third trimesters: Chronic use may lead to fetal adrenal sup. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.